Invokana has been subject to intense scrutiny and speculation because last year a similar drug, Forxiga (generic name dapagliflozin), developed by Bristol-Myers Squibb in partnership with AstraZeneca, was rejected by the FDA. The reason for the rejection was concern over liver damage and cancer risk, specifically breast cancer and bladder cancer.

FORBES: New Diabetes Drug Invokana Has Major Treatment - And Market - Potential

One reason for rejecting sulphate hazing out of hand might be the damage it could do to the ozone layer.

ECONOMIST: Geoengineering

Others stated, however, that the potential for large damage awards from private lawsuits provides a reason to limit private rights of action.

FORBES: Will a 'Privacy Bill of Rights' Include the Right to Class Action Lawsuits?

Aside from the potential for catastrophic environmental damage, Gorgon is risky for another reason.

FORBES: Chevron: The World's Biggest Gusher